Agilent Technologies (A) saw its stock surge 5.52% in pre-market trading on Thursday, following the release of its impressive fiscal second-quarter earnings report and raised full-year revenue guidance. The life sciences company's strong performance has caught the attention of investors and analysts alike.

According to the latest reports, Agilent posted better-than-expected fiscal second-quarter earnings, demonstrating the company's resilience and growth potential in the current market environment. In a move that further bolstered investor confidence, Agilent also raised its fiscal-year revenue guidance, signaling optimism about its future performance.

The positive sentiment surrounding Agilent is reflected in the numerous analyst ratings that followed the earnings release. TD Cowen maintained a Buy rating on Agilent, with analyst Daniel Brennan setting a price target of $150. Similarly, J.P. Morgan analyst Rachel Vatnsdal reiterated a Buy rating with a $155 price target, while Citi analyst Patrick B Donnelly maintained a Buy rating with a $165 price target. These bullish stances from major financial institutions underscore the market's confidence in Agilent's growth trajectory.

While JP Morgan slightly reduced its target price from $160 to $155, it's worth noting that the firm still maintains a Buy rating on the stock. This adjustment appears to have had little impact on investor enthusiasm, as evidenced by the significant pre-market stock movement.

As the market opens, investors will be closely watching Agilent's performance to see if the pre-market gains hold or potentially expand further. The company's strong results and positive outlook, coupled with favorable analyst sentiment, suggest that Agilent may be well-positioned for continued growth in the life sciences sector.